All Brands Owned by Bristol Myers Squibb Company

What does Bristol Myers Squibb own?
BMS owns a portfolio of prescription drug brands including Opdivo, Eliquis (co-marketed with Pfizer), Revlimid, Breyanzi, Abecma, Camzyos, Reblozyl, Cobenfy, Opdualag, Zeposia, and Krazati, plus the acquired pipelines of Celgene, Karuna, and Mirati.

Is Bristol Myers Squibb publicly traded?
Yes. Bristol Myers Squibb trades on the New York Stock Exchange under ticker BMY and is an S&P 500 component. The stock has been publicly listed since the Bristol-Myers side's earlier history, with the merged company trading since 1989.

Who founded Bristol Myers Squibb?
The modern company was created by merger in 1989 rather than founded by an individual. Its roots trace to William McLaren Bristol and John Ripley Myers, who founded Bristol-Myers in 1887, and Edward Robinson Squibb, who founded Squibb in Brooklyn in 1858.

Where is Bristol Myers Squibb headquartered?
BMS is headquartered in Princeton, New Jersey, after relocating its corporate offices to the Princeton area. The company has maintained New Jersey roots since the merger era, with major research sites across the state.

How many brands does Bristol Myers Squibb own?
BMS markets roughly two dozen major product brands globally, led by Eliquis, Opdivo, and the growing Growth Portfolio drugs. As a pharmaceutical company its brands are prescription medicines rather than consumer-facing labels.

Who owns Bristol Myers Squibb?
BMS is owned by public shareholders, with Vanguard, BlackRock, and State Street as the largest institutional holders. Christopher Boerner serves as board chair and chief executive officer. No single owner controls the company.